Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Atopic Dermatitis / Atopic Eczema – Landscape & Forecast – Disease Landscape & Forecast (G7)
Atopic dermatitis (AD) is a chronic inflammatory skin disease marked by pruritus and eczema. Key goals of AD treatment are to protect the skin barrier, reduce inflammation, and alleviate the itch…
Ulcerative Colitis – Geographic Focus: China – Ulcerative Colitis – China In-Depth (China)
Ulcerative colitis (UC) is a chronic, progressive inflammatory bowel disease marked by inflammation and ulceration of the colon and rectum. The primary objective of UC pharmacotherapy is to induce…
Chronic Urticaria – Landscape & Forecast – Disease Landscape & Forecast (G7)
The urticaria drug market is dominated by oral medications, including steroids and second-generation, nondrowsy antihistamines, which are prescribed for both chronic inducible urticaria (CIndU) and…
Chronic Urticaria – Current Treatment – Treatment Algorithms: Claims Data Analysis – Chronic Inducible Urticaria (US)
Chronic inducible urticaria (CIndU) encompasses various chronic urticaria subtypes caused by specific triggers. CIndU seems to be more resistant than chronic spontaneous urticaria (CSU) to…
Vitiligo – Current Treatment – Treatment Algorithms: Claims Data Analysis – Vitiligo (US)
Vitiligo is a chronic skin depigmentation disorder characterized by the destruction or loss of function of melanocytes. Its etiology and pathophysiology are not well understood but are believed to…
Chronic Urticaria – Current Treatment – Treatment Algorithms: Claims Data Analysis – Chronic Spontaneous Urticaria (US)
The drug market for chronic spontaneous urticaria (CSU) is dominated by oral medications, including those are approved (e.g., first- and second-generation antihistamines) and used off-label (e.g.,…
GLP-1 receptor agonists – China In-Depth – GLP-1 Receptor Agonists – China In-Depth – China
China’s GLP-1 receptor agonist market is set for robust expansion, driven by the rising prevalence of type 2 diabetes (T2D), obesity, and comorbidities such as chronic kidney disease (CKD) and…
